Gastrin-17 immunogen data

APHT said safety of the product has been demonstrated in a Phase I/II trial in the U.K. Induction of antibodies in the patients against their own hormone also was demonstrated.

Immunization of the first of two groups of patients in the trial is completed, and immunization of a second group has begun. The company declined to provide further information. ...